论文部分内容阅读
老年急性髓细胞白血病(AML)患者因其独特的生物学特性和临床特征,治疗预后较差。对于可耐受联合强化疗的患者在总体生存上较姑息治疗及对症治疗组有优势。不适合强化疗的老年患者可采用预激方案粒细胞集落刺激因子+阿克拉霉素+阿糖胞苷化疗,多药低剂量联合化疗。吉姆单抗适用于不能耐受标准化疗的老年AML患者。老年AML患者中自体移植受到限制,但有些患者可能从降低强度预处理的异基因造血干细胞移植中受益。
Elderly patients with acute myeloid leukemia (AML) due to its unique biological characteristics and clinical features, the prognosis is poor. Patients who tolerated combined intensive chemotherapy had an overall survival advantage over palliative and symptomatic treatment groups. Not suitable for intensive treatment of elderly patients can be pre-excitation program granulocyte colony stimulating factor + aclacinomycin + cytarabine chemotherapy, low-dose multi-drug combination chemotherapy. Gemtuzumab is suitable for elderly AML patients who can not tolerate standard chemotherapy. Autotransplantation is limited in elderly AML patients, but some patients may benefit from allogeneic hematopoietic stem cell transplantation that reduces the intensity of pretreatment.